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bstract
Aim.  –  The study was aimed at determining whether the dawn phenomenon in type 2 diabetes (T2D) can be predicted and quantified using
imple and easily accessible glucose determinations.
Methods.  –  A total of 210 non-insulin-treated persons with T2D underwent continuous glucose monitoring (CGM). The dawn phenomenon was
uantified as the absolute increment from the nocturnal glucose nadir to the pre-breakfast value (dawn, mg/dL). Pre-lunch (preL) and pre-dinner
preD) glucose, and their averaged values (preLD), were compared with the nocturnal nadir. These pre-meal values were subtracted from the
re-breakfast values. The differences obtained (pre-meal L, pre-meal D and pre-meal LD) were correlated with dawn values. The receiver
perating characteristic (ROC) curve was used to select the optimal pre-meal value that best predicted a dawn phenomenon, set at a threshold of
0 mg/dL.
Results.  –  All pre-meal glucose levels and differences from pre-breakfast values (pre-meal) significantly correlated (P  < 0.0001) with the
octurnal nadir and dawn values, respectively. The strongest correlations were observed for the parameters averaged at preL and preD time
oints: r  = 0.83 for preLD and r  = 0.58 for pre-meal LD. ROC curve analysis indicated that the dawn phenomenon at a threshold of 20 mg/dL
an be significantly predicted by a pre-meal LD cut off value of 10 mg/dL. The relationship between dawn (Y, mg/dL) and pre-meal LD (X,
g/dL) was Y = 0.49 X + 15.
Conclusion.  –  The self-monitoring of preprandial glucose values at the three main mealtimes can predict the presence/absence of the dawn
henomenon, and permits reliable assessment of its magnitude without requiring continuous overnight glucose monitoring.
 2014 Elsevier Masson SAS. All rights reserved.
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.  Introduction
The dawn phenomenon has been extensively investigated
or more than 30 years [1,2]. By using continuous glucose
onitoring (CGM), it has recently been demonstrated that, inon-insulin-treated persons with type 2 diabetes (T2D), the
awn phenomenon–defined as an excessive increment from the
octurnal glucose nadir to the pre-breakfast glucose value–is
∗ Corresponding author. Institute of Clinical Research, 641, avenue du Doyen-
iraud, 34093 Montpellier cedex 5, France. Tel.: +33 4 11 75 98 91;
ax: +33 4 11 75 98 98.
E-mail address: louis.monnier@inserm.fr (L. Monnier).
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http://dx.doi.org/10.1016/j.diabet.2014.10.002
262-3636/© 2014 Elsevier Masson SAS. All rights reserved. glycaemic disorder with a magnitude and frequency that are
elatively stable across all groups of subjects, irrespective of
reatment, HbA1c or age [3]. Its frequency can be as high as
0% [3], and its impact on HbA1c levels approximates 0.4%
4 mmol/mol) [4] and therefore cannot be ignored in the man-
gement of persons with T2D. Currently, healthcare providers
ail to take the dawn phenomenon into consideration as one of
he targets in the management of the disorder. This is very likely
inked to the fact that its quantification requires CGM to accu-
ately detect the nocturnal glucose nadir [4–7], and permit the
alculation of the absolute differences between the nocturnal
lucose nadir and pre-breakfast glucose values [3,4]. Access to
GM remains costly and is therefore only available to physicians
orking at clinics located in specialized diabetes units [8].
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Table 1
Characteristics of study patients.
Patients tested (n) 210
Age (years) 60.1 (0.7)
Body mass index (kg/m2) 30.4 (0.5)
Gender ratio (males/females) 134/76
Mean daily energy intake (kcal) 2193 (23)
Mean daily carbohydrate intake (g) 274 (3)
HbA1c (mmol/mol) 58 (0.9)
HbA1c (%) 7.5 (0.1)
Average 24 h mean glucose
concentrations (mg/dL)
144.8 (2.4)
Mean glucose value (mg/dL) at the
following time points
Nocturnal nadir 113.0 (2.3)
Pre-breakfast 131.4 (2.5)
Pre-lunch 126.5 (2.7)
Pre-dinner 121.1 (2.9)
Mean preLDa (mg/dL) 123.8 (2.4)
Diabetes treatment (patients, n)
Diet alone 6
Insulin sensitizers alone (metformin
and/or glitazones)
82
Insulin secretagogues/insulin
enhancers alone or in combination
with insulin sensitizers
122
 Dawnb (mg/dL) 18.4 (1.3)
Time of nocturnal glucose nadirc (h) 0341 [0157]
Data are expressed as means (SEM) unless stated otherwise.
a Averaged mean glucose values at pre-lunch and pre-dinner time points.
b Difference between pre-breakfast and nocturnal nadir glucose values.
c Calculated only for patients (n = 80) exhibiting an overt dawn phenomenon,
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Thus, any attempt to increase awareness of the dawn phe-
omenon and its management requires a simpler method for
ts quantification. Such a method would ideally be based on an
ppropriate cost-effective frequency of self-monitoring of blood
lucose (SMBG) in people with T2D [9]. However, structured
MBG is inadequate for detecting glucose nadirs, especially
hose occurring during nocturnal periods [3,4]. Consequently,
he question is whether SMBG at specific time points of the
iurnal period can provide an alternative in clinical practice for
etecting the presence of the dawn phenomenon and further
uantifying its magnitude. Using CGM through an observa-
ional study, the present study set out to ascertain, first, whether
ne or several preprandial or interprandial glucose values could
pproximate the nocturnal glucose nadir and, second, whether it
s possible to predict the presence or absence of the dawn phe-
omenon by calculating the decrement or increment between
re-breakfast glucose levels and those observed at other pre-
eal time points.
.  Methods
A total of 210 persons with T2D (mean age = 60.1 years, mean
ody mass index [BMI] = 30.4 kg/m2 and mean HbA1c = 7.5%
58 mmol/mol]) were selected after screening for eligibility from
 total population of 242 non-insulin-treated patients with T2D
ho underwent 3-day ambulatory CGM. The key criteria for
xclusion from the initial screened list of potential participants
ncluded having abnormal eating habits or eating patterns char-
cterized by unexpected food intakes during both diurnal and
octurnal periods. All participants who reported at least one
linical hypoglycaemic event over the test period were also
xcluded to avoid any misinterpretation due to either glucose
ises in the early morning or excessive glucose rebound after
orrection of the hypoglycaemic episode. To avoid any inter-
erence of carbohydrate intake on pre-meal glucose values, all
ndividuals for whom the time intervals between two consecutive
eals were < 4 h were also excluded. Accordingly, all subjects
ho reported having a mid-afternoon snack were excluded from
he final analysis. Additional criteria for exclusion were a recent
llness or treatment with steroids during the preceding 3 months,
nd any disruption in glucose monitoring or an insufficient num-
er of blood glucose tests for calibration during CGM (four tests
 day are required for this purpose). Unacceptable calibration
eant an accuracy criterion with a coefficient correlation < 0.79.
All study participants were investigated from 2003 to
011 at the outpatients facilities of the University Hospi-
al in Montpellier, France, and placed on a stable treatment
egimen with either dietary measures alone or the addition
f oral hypoglycaemic agents (OHAs) for at least 3 months
rior to CGM. Modalities of treatment were classified into
hree categories: (i) dietary measures alone (n  = 6); (ii) insulin
ensitizers alone (metformin and/or pioglitazone, n  = 82); and
iii) insulin secretagogues (sulphonylureas, glinides) or incretin
nhancers (dipeptidyl peptidase [DPP]-4 inhibitors) taken alone
r in combination with insulin sensitizers (n  = 122). DPP-4
nhibitors were categorized along with sulphonylureas and glin-
des because these drugs are all insulinotropic agents, although
l
3
e
w
xpressed as mean [SD].
he mechanism of action of DPP-4 inhibitors is much broader
han its effects on insulin secretion alone [10]. This categoriza-
ion has previously been used [4] and justified in a letter [11] in
esponse to a question raised by Carr et al. [12]. In addition, no
ifferences were observed between glycaemic profiles in the two
ain groups selected by categories of treatment (insulin sensi-
izers alone, and either insulin secretagogues/insulin enhancers
lone or in combination with insulin sensitizers). This lack of
ifference (data not shown) has reinforced our strategy to ana-
yze our study population as a whole, and not as separate groups
ategorized by type of antidiabetic treatment.
Dietary measures were based on a weight-maintaining diet
ith three main meals per day and with carbohydrates providing
0% of the total daily energy intake. Energy intake was assumed
o be equal to total energy expenditure. The latter was determined
y calculating the basal metabolic rate using Schofield’s equa-
ions [13] and then multiplying the result by 1.35, a coefficient
hat corresponds to a sedentary lifestyle with low physical activ-
ty, as seen in most of our patients. A daily ratio of 1:2:2 was
ecommended for calorie and carbohydrate distributions across
reakfast, lunch and dinner, respectively. The expected mean
aily energy and carbohydrate intakes estimated by this calcu-
ation are shown in Table 1. At the beginning and end of each
-day study period, dietary recommendations were carefully re-
mphasised and validated by trained dietitians, and instructions
ere given to all participants to help them maintain their current
1  Metabolism 41 (2015) 132–137
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Fig. 1. Graphic representation of calculations of the differences between glu-
cose values at pre-meal time points and the nocturnal nadir. Glucose values
(GVs) at the nocturnal nadir and pre-breakfast (BF), pre-lunch (L) and pre-
dinner (D) time points are indicated by numbers 1, 2, 3 and 4, respectively. GVs
for dawn, pre-meal L and pre-meal D are indicated by a, b and c, respec-
tively. preLD: average of pre-lunch (preL) and pre-dinner (preD) GVs; dawn:
difference between pre-breakfast and nocturnal nadir GVs; pre-meal L: dif-
ference between pre-breakfast and preL GVs; pre-meal D: difference between
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outine low-level physical activity while avoiding any vigorous
xercise.
All investigations were routinely performed at diabetes out-
atients clinics and were in compliance with the Helsinki
eclaration [14]. The study was conducted after each subject
ad given oral informed consent in accordance with European
irectives that require no approval from an ethics committee for
he non-interventional protocol described below [15].
.1.  Clinical  investigations  and  laboratory  determinations
All participants underwent ambulatory CGM for 3 consecu-
ive days, using the same technology, between 2003 and 2011
a second-generation MiniMed system, Medtronic, Inc., Min-
eapolis, MN, USA). The glucose sensor was inserted on day 0
nd removed mid-morning on day 3. Sensor insertion for CGM
as made on Monday/Tuesday and removal on Thursday/Friday
o avoid any overlap into the weekend. All calculations were
erived from data obtained over a 48 h period during days 1 and
 to avoid any bias due to either insertion or removal of the
ensor. Status of chronic hyperglycaemia (ambient hypergly-
aemia) was assessed on study day 0 by HbA1c levels that were
etermined using a high-performance liquid chromatography
HPLC) assay [16–18]. The intra- and interassay coefficients of
ariation (CVs) were < 2%, with a non-diabetic reference range
f 16.7–32.1 mmol/mol (3.7–5.1%) for HbA1c.
.2.  Analysis  of  data  obtained  by  CGM
CGM was used to detect the nocturnal glucose nadir and to
uantify glucose levels at pre-meal time points. The latter were
etermined in accordance with the data recorded by participants
n their own SMBG log books. All CGM readings were concomi-
antly made by two investigators using the same methodology
or data analysis and interpretation of the glycaemic profiles
btained from 2003 to 2011. All measurements provided by
GM were presented after averaging the data recorded on study
ays 1 and 2. This strategy was used to attenuate the day-to-day
uctuations seen in glucose profiles, including those of the dawn
henomenon.
The dawn phenomenon–defined as the spontaneous glucose
ise during the early morning hours–was quantified by sub-
racting the glucose nadir from the glucose value observed just
efore breakfast. Although measurements of glucose in the
nterstitial fluid from CGM readings are known to be lower
han venous plasma glucose concentrations [19], it should be
oted that, in the present study, the dawn phenomenon was
ssessed only from differences between interstitial values. The
pward glycaemic variation that occurs at night was only con-
idered a dawn phenomenon if its magnitude exceeded the
hreshold of 20 mg/dL, chosen on the basis of two main obser-
ations/principles that reflect what we know of the spontaneous
ariability and fluctuations of glucose levels [4]. First, a value
f 20 mg/dL approximates the 95% confidence interval (CI)
f total intra- and interassay variability seen in relation to a
rue fasting glucose concentration of 126 mg/dL [20]. Second,
his value of 20 mg/dL is above the spontaneous between-day
f
m
p
re-breakfast and preD GVs; pre-meal LD: difference between pre-breakfast
nd preLD (average of preL and preD) GVs.
uctuation in mean difference from nocturnal glucose nadir to
re-breakfast glucose values which, at an individual level, was
5 mg/dL (interquartile range [IQR]: 0–21.0 mg/dL) [4]. Pre-
unch (preL), pre-dinner (preD) and the averaged glucose values
t preL and preD time points (preLD) were tested as surrogates
f nocturnal glucose nadirs when tested against pre-breakfast
lucose values to quantify the magnitude of dawn glucose rises
uring the early morning hours.
.3.  Calculations  and  statistical  analyses
Mean glucose values were calculated at the nocturnal nadir
nd at pre-meal time points, and compared by analysis of vari-
nce (ANOVA) testing. The relationships between pre-meal
lucose values and nocturnal nadirs were calculated using Pear-
on’s test. Differences (pre-meal) between the pre-breakfast
nd other pre-meal values, such as preL, preD and the averaged
reLD, were calculated (mg/dL) and presented as pre-meal L,
pre-meal D and pre-meal LD, respectively. Details of the
alculation are illustrated in Fig. 1. All pre-meal values were
urther analyzed for statistical comparison and correlation with
he magnitude of the dawn glucose rise (dawn, mg/dL), deter-
ined according to the method mentioned above (by calculating
he glucose increment from nocturnal nadir to pre-breakfast time
oint). It should be noted that, in all cases, the dawn glucose rise
dawn) was quantified as ≥  0 while the differences between
re-meal values (pre-meal) could be affected by either a pos-
tive or negative sign, depending on whether the glucose values
easured at preL and preD time points and calculated from the
reLD were below or above the pre-breakfast glucose levels.
elationships between the dawn and pre-meal values were
urther tested using Pearson’s correlation coefficient.
The performance for detecting the most appropriate pre-
eal that can be used as a cut off value for detecting the dawn
henomenon was tested. For that purpose the threshold for the
L. Monnier et al. / Diabetes & Metabolism 41 (2015) 132–137 135
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ig. 2. a: Relationship between nocturnal nadir (Y, mg/dL) and the average of pr
s Y = 0.82 X + 11; b: Relationship between the dawn (Y, mg/dL) and the pr
resence or absence of a dawn phenomenon was set at 20 mg/dL,
 value selected on a previously described basis [4]. Sensitivity
nd specificity for predicting the presence or absence of a dawn
henomenon were calculated at different levels of pre-meal
differences between the pre-breakfast and other measured or
alculated pre-meal glucose values, using step-by-step incre-
ents from a negative [–30 mg/dL] to a positive [+30 mg/dL]
alue). Sensitivity (the true-positive fraction, TPF) was defined
s the proportion of subjects to have a dawn phenomenon
> 20 mg/dL) in relation to those who indeed had one, while
pecificity was defined as the proportion of subjects predicted to
ot have a dawn phenomenon (≤  20 mg/dL) in relation to those
ho actually did not. The optimal cut off differences between the
re-breakfast and other measured or calculated pre-meal values
pre-meal) was selected by an ROC curve constructed by plot-
ing sensitivity against the false-positive fraction (1–specificity,
PF) over ranges of the pre-meal cut off points [21]. The
ptimal cut off point balancing sensitivity and specificity was
elected at the shoulder of the ROC curve. The area under the
urve (AUC) was calculated using ROCKIT software (avail-
ble from the University of Chicago Department of Radiology
ebsite) [22].
.  Results
Clinical and laboratory data for the entire study population
n = 210) are included in Table 1.
.1.  Glucose  values  at  pre-meal  time  points  vs.  nocturnal
adirs
Mean pre-meal glucose values were seen to progressively
ecrease throughout the day from pre-breakfast to preD
ime points when the study population was considered as
 whole (Table 1). All mean pre-meal glucose values were
ignificantly greater (P  < 0.0001) than the nocturnal nadir of
13.0 ±  2.3 mg/dL (mean ±  SEM).
L
w
a
fi
t
 preD glucose values (X, preLD, mg/dL): r = 0.83, P < 0.0001. The relationship
l LD (X, mg/dL): r = 0.58, P < 0.0001. The relationship is Y = 0.49 X + 15.
.2.  Relationships  between  nocturnal  nadir  and  measured
r averaged  pre-meal  glucose  values
There was a strongly significant correlation (P  < 0.0001)
etween pre-meal glucose values, whether measured at preL
r = 0.78) or preD time points (r  = 0.77), when tested against
octurnal glucose nadirs. When glucose values were averaged
ver preL and preD time points (preLD), an even better corre-
ation was seen with the nocturnal nadir (r  = 0.83, P  < 0.0001).
ultiple comparisons across the three correlation coefficients
howed no significant differences. As illustrated in Fig. 2a, the
elationship between the preLD and nocturnal glucose nadir,
onsidered the “predictor” (X axis, mg/dL) and “response” (Y
xis, mg/dL) variables, respectively, was close to the identity
ine: Y = 0.82 X + 11. As a consequence, the pre-meal LD was
sed to calculate the cut off value that was able to predict, with
atisfactory and balanced sensitivity and specificity, the pres-
nce or absence of the dawn phenomenon when the increment
o define this glycaemic disorder was set at 20 mg/dL.
.3.  Relationships  between  magnitude  of  dawn
henomenon  (dawn)  and  measured  or  averaged
pre-meal values
All measured and averaged pre-meal values correlated with
he dawn value. However, the correlation with the greatest
ignificance was observed when dawn (Y axis, mg/dL) was
orrelated with the calculated pre-meal LD (X axis, mg/dL):
 = 0.58, P  < 0.0001. Fig. 2b presents a graph of the relationship:
 = 0.49 X + 15.
The ROC curve calculated from the stepwise increase in
pre-meal LD values with a 20 mg/dL threshold for the dawn
henomenon indicates that the best cut off point for a pre-meal
D predicting the absence or presence of a dawn phenomenon
as 10 mg/dL, with an FPF threshold of 0.32 (specificity = 68%)
nd a sensitivity of 71% (Fig. 3). In addition, significant and suf-
cient accuracy can be attributed to this predictive threshold as
he area under the ROC curve was 0.76, a value recognized as
136 L. Monnier et al. / Diabetes & Met
Fig. 3. Receiver operating characteristic (ROC) curve derived from the stepwise
increase in pre-meal LD. The threshold for defining the absence/presence of
a dawn phenomenon (dawn) was set at 20 mg/dL. The cut off value of pre-
meal LD for optimal prediction of the absence/presence of a dawn phenomenon
(the optimal balance between highest sensitivity and specificity) is 10 mg/dL,
indicated in the box at the shoulder of the ROC curve. The true-positive
fraction (Y = sensitivity) and the false-positive fraction (X = 1–specificity) indi-
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ate/reflect the specificity and sensitivity, respectively, of the pre-meal LD for
redicting a dawn phenomenon at a threshold of 20 mg/dL.
eing in the fair range (0.70–0.80) according to the traditional
cademic point system [21].
.  Discussion
The present results indicate that the nocturnal glucose nadir
ccurred at an average clock time of 03 h 41 in the morning,
hich has previously been reported as corresponding to the
octurnal growth hormone peak and the beginning of the pro-
ressive increase in cortisol, epinephrine and norepinephrine in
he early morning period/end of the night [23]. This nocturnal
lucose nadir was well correlated with all daytime pre-meal
alues, although the correlation improved when the preL and
reD values were averaged. Based on these results, we tested
he accuracy of the relationship between the magnitude of the
awn glucose rise (dawn; the difference between the noc-
urnal nadir and pre-breakfast value) vs.  the other pre-meal
alues, especially the pre-meal LD (the difference between
he pre-breakfast value and averaged glucose values at preL and
reD time points). As mentioned above, the present study gave
articular attention to the latter difference, as our results had
hown that this parameter was better correlated with the mag-
itude of the dawn glucose rise during the early morning hours
han with any of the other individual pre-meal values. Fur-
hermore, using stepwise analysis of the pre-meal LD and
alculating the ROC curves on the basis of the presence or
bsence of a dawn phenomenon at a threshold level of 20 mg/dL,
t was found that the dawn phenomenon could be fairly pre-
icted by a cut off value of 10 mg/dL for the averaged pre-meal
D.
o
p
o
abolism 41 (2015) 132–137
For obvious reasons, nocturnal glucose values cannot be
asily measured in clinical practice by discontinuous SMBG.
herefore, it appears that defining a cut off point derived from the
veraged pre-meal LD as a predictor of the dawn phenomenon
ay be of importance, although many other barriers are yet to be
vercome before the majority of healthcare providers can obtain
asy access to such new technologies as CGM [8].
Consequently, as discontinuous self-monitoring of glucose
oncentrations at the three pre-meal time points is easily avail-
ble in clinical practice, the difference between preLD and
re-breakfast glucose levels can be used as a substitute for
etecting the presence or absence of the dawn phenomenon and
s a reliable surrogate for its quantification. Measurements of
reD, preL and pre-breakfast glucose values can easily be inte-
rated into a patient-centred programme of structured SMBG,
ven in persons with T2D not treated with insulin. Such mea-
urements would also be helpful for making both patients and
heir healthcare providers aware of the presence of a dawn phe-
omenon. Indeed, such a glycaemic disorder should not be
gnored, given its global impact on HbA1c of approximately
.4% (4 mmol/mol) [4]. The dawn phenomenon is probably one
f the earlier disorders in the natural history of T2D [23,24]. In
ddition, through one of its consequences–the extended dawn
henomenon, characterized by excessive post-breakfast glucose
xcursions during the morning period–the dawn phenomenon
an contribute to overall glucose exposure in T2D [3–5,25].
onsequently, the dawn phenomenon should be taken into con-
ideration in the management of T2D, and its presence should
nstigate the use of more aggressive therapy as early as pos-
ible in the time course of the disease. At present, little or no
onsideration is given to the dawn phenomenon by the various
rganizations that have published clinical guidelines or stan-
ards of medical care in diabetes [26,27], not even when these
ecommendations are made within a patient-centred approach
28].
The present study offers healthcare professionals a relatively
imple method for assessing and quantifying the presence of
he dawn phenomenon and, thus, its integration into the man-
gement process. Three measurements of blood glucose at the
re-breakfast, preL and preD time points, and the subsequent
alculation of differences between the pre-breakfast glucose and
he average of the preL and preD glucose values, will allow pre-
iction of the absence/presence of a dawn phenomenon with a
atisfactory balance between sensitivity (71%) and specificity
68%). In addition, this method provides a practical, realistic
nd reliable assessment of the magnitude of the dawn phe-
omenon that can be calculated by a formula generated from
nalysis of our results: Y = 0.49 X + 15, where X is the difference
etween pre-breakfast glucose and the averaged preL and preD
lucose values (pre-meal LD). From a clinical point of view,
his calculation would be of interest in determining whether the
awn phenomenon should be taken into account for the given
ndividual. In addition, when treat-to-target strategies aimed at
owering the pre-breakfast glucose value to < 100 mg/dL are rec-
mmended, it is crucial to estimate the magnitude of the dawn
henomenon and reduce it to < 20 mg/dL to avoid the occurrence
f overnight hypoglycaemia.
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